Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.

Alfredo Rebora suggested a new, easier way to classify hair loss in Telogen Effluvium, adding a type possibly related to autoimmune diseases.

Hair loss in Telogen effluvium is often chronic, linked to stress, and lacks a confirmed treatment, but topical corticosteroids may be used.

After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.

The article concludes that different types of hair loss require specific treatments and psychological support is important.

Dermoscopy shows that diffuse alopecia areata progresses through specific hair growth stages.

Telogen Effluvium is a common hair loss condition, particularly in women, with no specific FDA-approved treatment, and recovery can take up to 18 months.

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.

People with hair loss conditions may also have thyroid disorders, but more research is needed to understand the connection.

Hair growth and shedding are linked and can be disrupted, causing a delay known as the hair eclipse phenomenon, which is common in certain hair conditions and could lead to new treatments.

The document explains hair growth and shedding, factors affecting it, and methods to evaluate hair loss, emphasizing the importance of skin biopsy for diagnosis.

AGA causes hair loss by shrinking hair follicles due to DHT binding, and can be treated with finasteride and minoxidil.

A systematic approach is crucial for managing hair loss in women.

Healthy women tend to lose more hair in July and April, and the least in February.

The article concludes that developing in vitro models for human hair structures is important for research and reducing animal testing, but there are challenges like obtaining suitable samples and the models' limitations.

Male pattern baldness involves genetics, hormones, and needs better treatments.

Dandruff is mainly caused by a scalp reaction to yeast, can worsen hair loss, and antifungal treatments may help.

Low-level laser therapy may improve hair regrowth and thickness for androgenetic alopecia, but more research is needed.

The conclusion is that future hair loss treatments should target the root causes of hair thinning, not just promote hair growth.

Different types of dog hair loss are linked to problems starting the hair growth phase and early hair cycle ending.

Hormonal changes after childbirth and menopause can lead to women's hair loss and facial hair growth, with a need for better treatments.

Understanding hair follicle biology and stem cell control could lead to new hair loss treatments.

EPR spectroscopy showed that spontaneous hair growth results in thicker skin and less pigmented hair than depilation-induced growth.

Hair characteristics might be early signs of Type 2 Diabetes and could help with early prevention.

Understanding hair biology is key to developing better treatments for hair and scalp issues.

The study suggests that a new protease inhibitor can make hair harder to pull out, potentially reducing hair loss.

CTE and FPHL are different hair loss types with unique causes.

Algal oligosaccharides help prevent hair loss and promote hair growth.